AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18259972 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 15 micro g BID
Number of subjects: 1456
Study 18259972 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 25 micro g BID
Number of subjects: 1456
Study 18259972 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 50 micro g QD
Number of subjects: 1456
Study 18259972 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micro g BID
Number of subjects: 1456
Study 18259972 — intervention group
Group type: COMPARATOR
Intervention: Arformoterol
Number of subjects: 1456
Study 18259972 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 1456
Study 18259972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1456
Study 16806442 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal pelvic lymphadenectomy (TPL)
Number of subjects: 168
Study 16806442 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal pelvic lymphadenectomy (EPL)
Number of subjects: 168
Study 16806442 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic lymphadenectomy (LPL)
Number of subjects: 168
Study 15636035 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib preoperatively (40 mg IM/IV)
Number of subjects: 80
Study 15636035 — intervention group
Group type: COMPARATOR
Intervention: Parecoxib postoperatively (40 mg IM/IV)
Number of subjects: 80
Study 10862371 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer
Number of subjects: 0
Study 10862371 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9165581 — intervention group
Group type: EXPERIMENTAL
Intervention: 560 mg estramustine phosphate (EMP) per day
Number of subjects: 197
Study 9165581 — intervention group
Group type: COMPARATOR
Intervention: 3 mg diethylstilbestrol (DES) per day
Number of subjects: 197
Study 8109834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 0
Study 8109834 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction radiography
Number of subjects: 0
Study 8109834 — intervention group
Group type: EXPERIMENTAL
Intervention: Further studies
Number of subjects: 0
Study 3897460 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lecithin (20-25 g/day of purified soya lecithin for six months)
Number of subjects: 51
Study 3897460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 2903827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dosing of xamoterol
Number of subjects: 8
Study 2903827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dosing of xamoterol
Number of subjects: 8
Study 2903827 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pharmacokinetics in cardiac failure patients vs young healthy male volunteers
Number of subjects: 8
Study 31353758 — intervention group
Group type: EXPERIMENTAL
Intervention: tSMS over the left auditory cortex
Number of subjects: 15
Study 31353758 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 31353758 — intervention group
Group type: EXPERIMENTAL
Intervention: tSMS over the right auditory cortex
Number of subjects: 15
Study 29299661 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-EXACT (TVT-E)
Number of subjects: 125
Study 29299661 — intervention group
Group type: COMPARATOR
Intervention: TVT-ABBREVO (TVT-A)
Number of subjects: 125
Study 27237709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg b.d. for 52 weeks
Number of subjects: 111
Study 27237709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial treatment)
Number of subjects: 111
Study 27237709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol treatment
Number of subjects: 111
Study 24636040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 2.5 mg (pilot low dose determination study)
Number of subjects: 14
Study 24636040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 35 mg (single-dose PK study)
Number of subjects: 14
Study 23276888 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) with oral calcium and vitamin D supplementation
Number of subjects: 74
Study 23276888 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral calcium and vitamin D supplementation only)
Number of subjects: 74
Study 20451546 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.05, 0.1, 0.25, 0.5 and 1mg at 15min intervals)
Number of subjects: 20
Study 20451546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17655781 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (30 µg kg-1)
Number of subjects: 211
Study 17655781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 17655781 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 211
Study 16868708 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA, MMF, Steroids and Basiliximab (Group A)
Number of subjects: 26
Study 16868708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus, MMF, Steroids and Daclizumab (Group B)
Number of subjects: 26
Study 15178717 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU/mL r‐UK
Number of subjects: 108
Study 15178717 — intervention group
Group type: EXPERIMENTAL
Intervention: 15,000 IU/mL r‐UK
Number of subjects: 108
Study 15178717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU/mL r‐UK
Number of subjects: 108
Study 15178717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 11102257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta-brachytherapy (90Sr/90Y source)
Number of subjects: 31
Study 11102257 — intervention group
Group type: COMPARATOR
Intervention: Control (non-irradiated)
Number of subjects: 31
Study 11102257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subsegments (<6 Gy)
Number of subjects: 31
Study 11102257 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective-dose subsegments (>=6 Gy)
Number of subjects: 31
Study 11102257 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated subsegments
Number of subjects: 31
Study 11102257 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated subsegments
Number of subjects: 31
Study 9316529 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (maximal dose 50 mg three times daily for 6 months)
Number of subjects: 15
Study 9316529 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (5 to 10 micrograms/kg body weight per min)
Number of subjects: 15
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.75 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (6 mg/70 kg)
Number of subjects: 8
Study 8450459 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg for both drugs)
Number of subjects: 8
Study 3536530 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 18
Study 3536530 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 18
Study 30832692 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulation of RNF128
Number of subjects: 0
Study 30832692 — intervention group
Group type: EXPERIMENTAL
Intervention: RNF128 interference
Number of subjects: 0
Study 30832692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RNF128 expression
Number of subjects: 0
Study 29239943 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia
Number of subjects: 117
Study 27394195 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 4262
Study 27394195 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4262
Study 24818523 — intervention group
Group type: EXPERIMENTAL
Intervention: banked human milk plus 5% commercial fortifier with bovine protein
Number of subjects: 24
Study 24818523 — intervention group
Group type: EXPERIMENTAL
Intervention: banked human milk plus evaporated fortifier derived from modified human milk
Number of subjects: 24
Study 24818523 — intervention group
Group type: EXPERIMENTAL
Intervention: banked human milk plus lyophilized fortifier derived from modified human milk
Number of subjects: 24
Study 22870238 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily)
Number of subjects: 612
Study 22870238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrients without zinc
Number of subjects: 612
Study 22870238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 20420586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015% eye drops
Number of subjects: 533
Study 20420586 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% eye drops
Number of subjects: 533
Study 18528875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based thin-ideal internalization reduction program
Number of subjects: 481
Study 18528875 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy weight management program
Number of subjects: 481
Study 18528875 — intervention group
Group type: COMPARATOR
Intervention: Expressive-writing control condition
Number of subjects: 481
Study 18528875 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 481
Study 16046689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging smoking cessation programme
Number of subjects: 1705
Study 16046689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messaging until six months)
Number of subjects: 1705
Study 11891670 — intervention group
Group type: EXPERIMENTAL
Intervention: S-verapamil
Number of subjects: 0
Study 11891670 — intervention group
Group type: EXPERIMENTAL
Intervention: R-verapamil
Number of subjects: 0
Study 10618615 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 37
Study 10618615 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoradiotherapy (TRT) with 3 sessions of hyperthermia plus RT
Number of subjects: 37
Study 9181506 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous fixation using K‐wires, followed by casting
Number of subjects: 40
Study 9181506 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and casting
Number of subjects: 40
Study 8243878 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (65 micrograms/kg)
Number of subjects: 0
Study 8243878 — intervention group
Group type: COMPARATOR
Intervention: Insulin (0.1 IU/kg)
Number of subjects: 0
Study 2938849 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective inhibitor of thromboxane synthase, imidazo (1,5‐2) pyridine‐5‐hexanoic acid, administered under randomized, double‐blind, controlled conditions.
Number of subjects: 0
Study 2938849 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (as a control for platelet cyclooxygenase inhibition)
Number of subjects: 0
Study 2938849 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dosing with the synthetic inhibitor of thromboxane synthase
Number of subjects: 0
Study 2938849 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboxane synthase inhibitor
Number of subjects: 0
Study 30709964 — intervention group
Group type: EXPERIMENTAL
Intervention: ALSDI (Amyotrophic Lateral Sclerosis Diagnostic Index) in the training cohort
Number of subjects: 407
Study 30709964 — intervention group
Group type: EXPERIMENTAL
Intervention: ALSDI in the test cohort
Number of subjects: 407
Study 30709964 — intervention group
Group type: EXPERIMENTAL
Intervention: ALSDI in Awaji negative patients
Number of subjects: 407
Study 30709964 — intervention group
Group type: EXPERIMENTAL
Intervention: ALSDI in patients with predominantly lower motor neuron phenotype
Number of subjects: 407
Study 28489288 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT‐E (Enhanced Cognitive Behavioral Therapy)
Number of subjects: 40
Study 28489288 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT‐E
Number of subjects: 40
Study 28489288 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study 25947202 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention to reduce teenage pregnancy; details on dosage and duration not available.
Number of subjects: 0
Study 25947202 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; control group not specified.
Number of subjects: 0
Study 23911273 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose-adjustment (CDA) according to PR monitoring
Number of subjects: 177
Study 23911273 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel therapy
Number of subjects: 177
Study 22235508 — intervention group
Group type: EXPERIMENTAL
Intervention: Biguanide (metformin 500 mg three times daily)
Number of subjects: 400
Study 22235508 — intervention group
Group type: COMPARATOR
Intervention: Statin (simvastatin 20 mg daily)
Number of subjects: 400
Study 22235508 — intervention group
Group type: EXPERIMENTAL
Intervention: Biguanide (metformin)
Number of subjects: 400
Study 22235508 — intervention group
Group type: COMPARATOR
Intervention: Statin (simvastatin)
Number of subjects: 400
Study 18977552 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroMeter NAFLD
Number of subjects: 235
Study 18977552 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD fibrosis score (NFSA)
Number of subjects: 235
Study 18977552 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 235
Study 16217850 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent assessment (16 postbaseline visits, twice-weekly for 8 weeks)
Number of subjects: 0
Study 16217850 — intervention group
Group type: COMPARATOR
Intervention: Traditional assessment (5 postbaseline visits at Weeks 1, 2, 4, 6, and 8)
Number of subjects: 0
Study 15271855 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% decreased vegetable intake (75 g/day) for 2 weeks
Number of subjects: 28
Study 15271855 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubled vegetable intake (300 g/day) for 2 weeks
Number of subjects: 28
Study 15271855 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls) receiving standard vegetable intake
Number of subjects: 28
Study 11011807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) tinzaparin, dosage regimen not specified
Number of subjects: 0
Study 11011807 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 11011807 — intervention group
Group type: COMPARATOR
Intervention: Reviparin
Number of subjects: 0
Study 11011807 — intervention group
Group type: COMPARATOR
Intervention: Tinzaparin
Number of subjects: 0
Study 9141585 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 (300 mg)
Number of subjects: 12
Study 9141585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9141585 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059
Number of subjects: 12
Study 8263640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 16 mg preoperatively and three placebo postoperative doses
Number of subjects: 23
Study 8263640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 16 mg preoperatively and three 8-mg postoperative doses
Number of subjects: 23
Study 8263640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3300664 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono)
Number of subjects: 0
Study 3300664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30265070 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Tinnitus Management (ITM)
Number of subjects: 30
Study 29362263 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA infant feeding intervention
Number of subjects: 0
Study 29362263 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26071390 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief risk reduction counselling at the time of HIV testing
Number of subjects: 1704
Study 26071390 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline presence of Trichomonas vaginalis (TV)
Number of subjects: 1704
Study 26071390 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline presence of chlamydia
Number of subjects: 1704
Study 26071390 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline presence of HIV
Number of subjects: 1704
Study 26311415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose (LD)
Number of subjects: 24
Study 26311415 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel loading dose (LD)
Number of subjects: 24
Study 26311415 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor and Prasugrel
Number of subjects: 24
Study 23092692 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (GG)
Number of subjects: 57
Study 23092692 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies combination containing Lactobacillus rhamnosus GG
Number of subjects: 57
Study 23092692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21636731 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly attractive other-sex targets
Number of subjects: 3
Study 21636731 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly attractive same-sex targets
Number of subjects: 3
Study 21636731 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with high self-esteem
Number of subjects: 3
Study 17531989 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue and rFSH and rLH (Group A)
Number of subjects: 84
Study 17531989 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogue and rFSH without further LH addition (Group B)
Number of subjects: 84
Study 16487108 — intervention group
Group type: EXPERIMENTAL
Intervention: Proderm (Pro‐Q in the USA) moisturizer
Number of subjects: 24
Study 16487108 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 healthy subjects)
Number of subjects: 24
Study 14725658 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm Nd:YAG laser at a fluence of 20 J/cm2 and a pulse duration of 50 ms
Number of subjects: 10
Study 14725658 — intervention group
Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser at a fluence of 25 J/cm2 and a pulse duration of 40 ms
Number of subjects: 10
Study 10861155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 3 microg/ml (60 microg) fentanyl
Number of subjects: 84
Study 10861155 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 84
Study 10861155 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 84
Study 9346454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 42
Study 9346454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 42
Study 9346454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8121733 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (Am)
Number of subjects: 31
Study 8121733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 31
Study 2552717 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 0
Study 790890 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 0
Study 31182293 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention during the holiday period
Number of subjects: 171
Study 31182293 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-weighing frequency during the holiday period
Number of subjects: 171
Study 31182293 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer intervention engagement during the holiday period
Number of subjects: 171
Study 27629796 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 117
Study 27629796 — intervention group
Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 117
Study 26541658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg q8 h orally for 7 days)
Number of subjects: 44
Study 26541658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 24368695 — intervention group
Group type: EXPERIMENTAL
Intervention: Music aerobic exercise (MAE) for 12 weeks
Number of subjects: 47
Study 24368695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MAE exercise)
Number of subjects: 47
Study 21964491 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (300 μg)
Number of subjects: 24
Study 21964491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19260880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 182
Study 19260880 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (watchful waiting)
Number of subjects: 182
Study 17763439 — intervention group
Group type: COMPARATOR
Intervention: Infliximab 3 mg/kg
Number of subjects: 122
Study 17763439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 17763439 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg (after crossover from placebo)
Number of subjects: 122
Study 17763439 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg
Number of subjects: 122
Study 16143712 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 192
Study 16143712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192